GlassScriptPhysician profile
Jayson Keener
NPI 1821575432
$4,768.11
in general payments reported to CMS, 2019-2025
38 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $244 · 2023: $1,068 · 2024: $1,662 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,802 · Education: $280 · Entertainment: $13.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,802.46 |
| Education | $279.57 |
| Entertainment | $13.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,072.36 | 2021-2025 | |
| Janssen Biotech, INC. | $643.46 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $352.29 | 2022-2025 | Mounjaro, Taltz, Olumiant |
| Ucb, INC. | $284.80 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $279.90 | 2024-2025 | Dupixent, Libtayo |
| Pfizer INC. | $210.21 | 2021-2025 | |
| Novo Nordisk INC | $199.57 | 2023 | Ozempic, Rybelsus, Wegovy |
| Sun Pharmaceutical Industries INC. | $197.17 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $127.35 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $124.52 | 2023 | Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.57 | 2023-2025 | Spevigo, Jardiance, Tradjenta |
| Incyte Corporation | $91.39 | 2022-2025 | Opzelura |
| Genzyme Corporation | $73.55 | 2025 | |
| Dermavant Sciences, INC. | $71.18 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $70.63 | 2024-2025 | Zoryve |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $70.14 | 2024-2025 | Sotyktu |
| Organogenesis INC. | $69.93 | 2024 | |
| Amgen INC. | $68.16 | 2023-2024 | Otezla, Repatha |
| Galderma Laboratories, L.P. | $62.44 | 2025 | Nemluvio |
| Almirall LLC | $58.76 | 2024-2025 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $58.04 | 2025 | |
| Vyne Pharmaceuticals INC. | $53.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.06 | 2023 | Xifaxan |
| Verrica Pharmaceuticals INC. | $47.03 | 2024-2025 | Ycanth |
| Janssen Pharmaceuticals, INC | $43.89 | 2023 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $43.42 | 2023 | Breztri, Farxiga |
| Leo Pharma INC. | $37.83 | 2021-2025 | Spevigo |
| Almatica Pharma LLC | $24.92 | 2023 | Gralise |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.13 | 2024 | Cabtreo |
| Merck Sharp & Dohme LLC | $22.94 | 2023 | Verquvo, Belsomra, Steglatro |
| Abbott Laboratories | $22.56 | 2023 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $19.34 | 2023 | Unithroid |
| Exact Sciences Corporation | $18.44 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $17.41 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $16.85 | 2023 | Trintellix |
| Strata Skin Sciences, INC. | $14.38 | 2024 | Xtrac |
| Optos, INC. | $13.93 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Keener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.